Banafshe Abadi

Dr. Banafshe Abadi

Pharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran
+1
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2020 in Molecules
Verified
Journal Article
Open access
PDF file
Mahshid Moballegh NaseryMahshid Moballegh Nasery
Mahshid Moballegh Nasery
Banafshe AbadiBanafshe Abadi
Banafshe Abadi
DMdeli mo
deli mo
Ali ZarrabiAli Zarrabi
Ali Zarrabi
PKPeyman Keyhanvar
Peyman Keyhanvar
Gautam SethiGautam Sethi
Gautam Sethi
Todays, nano-pharmaceutics is emerging as an important field of science to develop and improve efficacy of different drugs. Although nutraceuticals are currently being utilized in the prevention and treatment of various chronic diseases such as cancers, a number of them have displayed issues associated with their solubility, bioavailability, and bio-degradability. In the present review, we focus on curcumin, an important and widely used polyphenol, with diverse pharmacological activities such as anti-inflammatory, anti-carcinogenic, anti-viral, etc. Notwithstanding, it also exhibits poor solubility and bioavailability that may compromise its clinical application to a great extent. Therefore, the manipulation and encapsulation of curcumin into a nanocarrier formulation can overcome these major drawbacks and potentially may lead to a far superior therapeutic efficacy. Among different types of nanocarriers, biological and biopolymer carriers have attracted a significant attention due to their pleiotropic features. Thus, in the present review, the potential protective and therapeutic applications of curcumin, as well as different types of bio-nanocarriers, which can be used to deliver curcumin effectively to the different target sites will be discussed.

23 February 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MBMohammed Bhia
Mohammed Bhia
Mahzad MotallebiMahzad Motallebi
Mahzad Motallebi
Banafshe AbadiBanafshe Abadi
Banafshe Abadi
AZAtefeh Zarepour
Atefeh Zarepour
MPMiguel Pereira-Silva
Miguel Pereira-Silva
Mehdi ShakibaeiMehdi Shakibaei
Mehdi Shakibaei
Naringenin (NRG) is a polyphenolic phytochemical belonging to the class of flavanones and is widely distributed in citrus fruits and some other fruits such as bergamot, tomatoes, cocoa, and cherries. NRG presents several interesting pharmacological properties, such as anti-cancer, anti-oxidant, and anti-inflammatory activities. However, the therapeutic potential of NRG is hampered due to its hydrophobic nature, which leads to poor bioavailability. Here, we review a wide range of nanocarriers that have been used as delivery systems for NRG, including polymeric nanoparticles, micelles, liposomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), nanosuspensions, and nanoemulsions. These nanomedicine formulations of NRG have been applied as a potential treatment for several diseases, using a wide range of in vitro, ex vivo, and in vivo models and different routes of administration. From this review, it can be concluded that NRG is a potential therapeutic option for the treatment of various diseases such as cancer, neurological disorders, liver diseases, ocular disorders, inflammatory diseases, skin diseases, and diabetes when formulated in the appropriate nanocarriers.

1 December 2021 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
Banafshe AbadiBanafshe Abadi
Banafshe Abadi
NYNiloufar Yazdanpanah
Niloufar Yazdanpanah
Ali NokhodchiAli Nokhodchi
Ali Nokhodchi
NRNima Rezaei
Nima Rezaei

1 July 2021 in Fundamental & Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
Banafshe AbadiBanafshe Abadi
Banafshe Abadi
YSYasamin Shahsavani
Yasamin Shahsavani
MFMahsa Faramarzpour
Mahsa Faramarzpour
NRNima Rezaei
Nima Rezaei
HRHamid‐Reza Rahimi
Hamid‐Reza Rahimi

1 January 2021 in Hematology/Oncology and Stem Cell Therapy
Verified
Journal Article
Open access
Banafshe AbadiBanafshe Abadi
Banafshe Abadi
MAMeysam Ahmadi-Zeidabadi
Meysam Ahmadi-Zeidabadi
LDLuciana Dini
Luciana Dini
Cristian VergalloCristian Vergallo
Cristian Vergallo
Glioblastoma (GB) is one of the most malignant types of central nervous system tumours, classified as grade IV by the World Health Organization. Despite the therapeutic advances, the prognosis is ominous, with a median survival of about 12–15 months post diagnosis. Although therapeutic options available can increase the survival, they are ineffective in treating patients with GB. Impairing factors such as the blood–brain barrier, cancer stem cells, and infiltration into brain parenchyma lead to failure of current therapies. Therefore, clinicians need novel/alternative effective strategies to treat GB. Due to their ability to preserve healthy tissues and to provide an effective and long-lasting response, stem cells (SCs) with tropism for tumour cells have attracted considerable attention in the scientific community. As is the case here, SCs can be used to target brain tumour cancer cells, especially high-grade malignant gliomas like GB, by overcoming the resistance and exerting benefits for patients affected with such lethal disease. Herein, we will discuss the research knowledge regarding SC-based therapy for the treatment of GB, focalising our attention on SCs and SC-released extracellular vesicles modified to express/load different antitumour payloads, as well as on SCs exploited as a diagnostic tool. Advantages and unresolved issues of anticancer SC-based therapy will also be considered.

5 October 2023 in Heliyon
Verified
Journal Article
Open access
NSNazanin Sabet
Nazanin Sabet
Banafshe AbadiBanafshe Abadi
Banafshe Abadi
AMAmirhossein Moslemizadeh
Amirhossein Moslemizadeh
MRMohammad Amin Rajizadeh
Mohammad Amin Rajizadeh
FAFatemeh Arabzadeh
Fatemeh Arabzadeh
HBHamideh Bashiri
Hamideh Bashiri
This study was performed to evaluate the effects of low and moderate treadmill exercise for one month on social interaction, anxiety-like behaviors, and spatial learning and memory in male and female autistic rats. Pregnant rats received valproic acid (VPA) (600 mg/kg/i.p) once on gestational day 12.5 to induce autism-like symptoms in the offspring. After delivery, the offspring were divided into six main groups, each with male and female subgroups: Control (CTL, prenatal normal saline), autism (prenatal VPA), low-intensity training (LIT,normal saline + low treadmill exercise), moderate -intensity training (MIT, normal saline + moderate treadmill exercise), VPA + LIT, and VPA + MIT. On the 60th day, the offspring were tested by the elevated plus maze (EPM), open field test (OFT), social interaction test (SIT), and Morris water maze (MWM). The results showed that both LIT and MIT could partly alleviate anxiety-like behaviors induced by prenatal VPA exposure in two sexes. Social impairment was observed in the autistic rats and was improved by LIT in both sexes and MIT in females. No significant change was seen in the spatial learning and memory of autistic rats by exercise. The findings suggest that treadmill exercise can be helpful for improving some autism-like behaviors. Further studies are needed to investigate the involved mechanisms.